ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

Novartis: EU Backs Afinitor in Breast Cancer

ZURICH--The European Medicines Agency Friday recommended Novartis AG's (NVS) cancer drug Afinitor for approval in the European Union for the treatment of advanced breast cancer, supporting the Swiss company's hopes that the drug may become a blockbuster as it wins approval for use in different types of cancer. Novartis said the EMA's Committee for Medicinal Products for Human Use is backing the use of Afinitor tablets, in combination with hormone therapy, to treat advanced forms of breast cancer in certain women. The Basel-based company said it is submitting the drug for approval worldwide for a certain type of advanced breast cancer. If granted, this will be the fifth indication for Afinitor, which is already approved to treat kidney cancer, as well as certain kinds of brain and pancreatic tumors. Such extensions of the drug's therapeutic indications are likely to pave the way for Afinitor to become a best-seller thanks to its potential in various types of cancer. In April, the U.S. Food & Drug Administration granted wider approval to Afinitor, whose generic name is everolimus, to treat non-cancerous kidney tumors that don't require immediate surgery, after the drug was approved in the U.S. in 2009 to treat kidney cancer after treatment with other drugs failed. Afinitor, a pill taken once daily, blocks the uncontrolled activity of a protein called mTOR, which plays a role in the development and growth of certain tumors. EMA's nod is based on data from a late-stage trial involving 724 patients with HR+/HER2- advanced breast cancer, which affects an estimated 220,000 women globally each year. The study found that Afinitor combined with hormonal therapy increased the time it took cancer to progress to over seven months, compared with about three months using hormonal therapy alone. Novartis said the European Commission generally follows CHMP's recommendations and is expected to make a decision within three months. Write to Marta Falconi at marta.falconi@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
09/03/201513:11:00Novartis to Begin Selling Copy of Amgen's Neupogen in U.S.--3rd...
09/03/201507:14:00Novartis to Begin Selling Copy of Amgen's Neupogen in U.S...
09/03/201505:24:00Novartis to Begin Selling Copy of Amgen's Neupogen in U.S.
09/03/201504:00:00Novartis to Begin Selling Copy of Amgen's Neupogen in U.S.
09/03/201502:49:00Novartis to Begin Selling Copy of Amgen's Neupogen in US
09/02/201516:30:00Novartis Closer to Selling Copy of Amgen's Neupogen
09/02/201516:22:00Court Decision Could Allow Novartis To Sell Copy of Amgen's Neupogen...
09/02/201516:16:00Court Decision Could Allow Novartis To Sell Copy of Amgen's Neupogen
09/02/201502:00:00Amgen to Help Develop Novartis's Pipeline of Alzheimer's Drugs
09/01/201502:32:00Novartis Gets EU Approval For Skin Cancer Drugs Tafinlar, Mekinist
08/27/201519:20:00FDA Approves New Amgen Cholesterol Drug
08/21/201509:26:00Correction to Glaxo Sells Rights to Auto-Immune Drug to Novartis
08/21/201509:19:00Glaxo Sells Rights to Auto-Immune Drug to Novartis -- Update
08/21/201506:20:00Glaxo Sells Drug Rights to Novartis
08/21/201506:04:00Glaxa Sells Rights to Auto-Immune Drug to Novartis
08/21/201502:19:00GSK to Sell Rights in Ofatumumab for Auto-Immune Indications...
08/20/201503:03:00Novartis Gets EU Approval For Skin Cancer Treatment Odomzo
08/10/201509:15:00Active Equities to Watch in the Healthcare Sector -- AstraZeneca...
07/29/201508:10:07GSK Posts Sharp Fall in Profit
07/29/201507:29:46Novartis Spins Off Three Pipeline Drugs Into New Company

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad